Summary
Introduction
Suramin is a polysulphonated naphthylurea that has been used since the 1920s as a treatment for parasitic diseases such as trypanosomiasis and onchocerciasis. The clinical interest in this drug waned until recently when it was tested in a multi-centre clinical trial for treatment of patients with AIDS. Although the drug has been shown to inhibit retroviral reverse transcriptase in vitro, this treatment trial was unsuccessful (Mitsuya et al., 1984; Levine et al., 1986) . However, anti-tumour activity was noted in a patient with an HIV-associated Kaposi's sarcoma and indolent B-cell lymphoma. Subsequent trials in multiple cancer types demonstrated anti-tumour activity in hormonerefractory prostatic cancer (Stein et al., 1989; Myers et al., 1992; Eisenberger et al., 1993; Kelly et al., 1993;  © Oxford University Press 1996 Eisenberger et al., 1995; Kantoff, 1995; Kobayashi et al., 1995) and generated a resurgence of interest in this drug.
Clinical use of suramin is complicated by a broad spectrum of toxic effects. In a recent study (Eisenberger et al., 1993) , 80% of patients discontinued therapy because of dose-limiting toxic effects, with neurotoxicity being the most common. Although the neuropathy may be severe and potentially life-threatening, its precise incidence, severity, and characteristics remain unknown. Because of a possible relationship of greater toxicity with plasma levels 2^350 jig ml"' when the drug is delivered as a continuous infusion (Scher, 1993; Bitton et al., 1995) , an intermittent 5-day administration schedule was devised. As a part of this phase I study at the Johns Hopkins Cancer *Suramin was infused i.v. over 1-2 h (in 500 ml D5 NS). Dose is given as mg m~2 of body surface area.
Center, we undertook a prospective study to define and characterize suramin-induced neurotoxicity in this cohort of patients.
Subjects
Twenty-two patients receiving suramin for hormonerefractory prostate cancer were prospectively evaluated for neurotoxicity. Suramin was administered by a short daily infusion for 5 days; this schedule was repeated at monthly intervals in an escalating, pharmacologically based, fixed dose (Table 1) . Three cohorts were defined based on 30-min post-infusion suramin concentrations of 300 (ig ml" 1 (cohort I = 5 patients), 350 |ig ml" 1 (cohort II = 5 patients) and 400 |ig ml" 1 (cohort III = 12 patients). The study end-points were dose-limiting toxicity(ies) or disease progression.
Methods

Neurological evaluations
In all patients, neurological evaluations, using the total neuropathy score (TNS), were carried out at baseline and after every third cycle of treatment, as well as between these time periods if a patient became symptomatic or discontinued taking suramin (study termination). This strategy has been previously used to monitor toxic neuropathies (Chaudhry et al., 1994) .
The TNS consists of four principal parts, (i) A directed history is taken, specifically addressing symptoms of numbness, tingling or pain in the feet or fingers, weakness in the legs or arms, and any functional limitations produced by these symptoms, (ii) A directed neurological examination is given, focusing on quantifying abnormalities in sensation, strength and deep tendon reflexes, (iii) Nerve conduction studies are done to obtain the following values for each patient: (a) right sural and median sensory nerve action potential amplitudes and conduction velocities; (b) right common peroneal and median distal motor latencies and compound muscle action potential amplitudes; and (c) right posterior tibial H-reflex latency (limb temperature is maintained at >32°C at the dorsum of the foot or on the index finger), (iv) Quantitative sensory testing of vibratory and thermal (cooling) thresholds is done at the right foot and hand using CASE IV (WR Medical Electronics Co., Stillwater, Minn., USA). From these four measures, 10 components are abstracted; each component is then graded from 0 to 4, and combined to form the TNS, which therefore can range from 0 to 40 (Table 2) .
The pre-and post-treatment measurements for all parameters listed above were compared by paired t test. Linear regression analyses were performed for percent change in these values versus cumulative doses of suramin at the time of the last evaluation. Empirically, a change in the TNS of 5=5 was considered significant. Standard clinical, electrodiagnostic, laboratory (spinal fluid analysis) and pathological (nerve biopsy) criteria were used to reach a diagnosis of demyelinating polyneuropathy or lengthdependent axonal neuropathy (Asbury et al., 1978; Schaumberg and Spencer, 1979) .
Nerve pathology
Nerve biopsies were divided: one specimen was fixed in 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.4, and the other in 5% glutaraldehyde in the same buffer. Paraffin sections of the paraformaldehyde-fixed material were stained with haematoxylin and eosin and with a Naumienko-Feigin silver-luxol fast blue-periodic acid Schiff combination stain (McKhann et al., 1993) . In addition, paraffin sections were immunostained with anti-CD45 antibody (Dako. Carpinteria, Calif., USA) to identify lymphocytes and with HAM-56 antibody (Enzo, Syosset, NY, USA) to identify macrophages, as previously described (Hafer-Macko et al., 1996) .
The glutaraldehyde-fixed specimens were osmicated, embedded in Epon, sectioned at 1 |0.m, and stained with toluidine blue. In addition, these sections were etched (Hafer-Macko et al., 1996) and immunostained with HAM-56 to identify macrophages. For each etched section, the next section (with no intervening thick or thin sections) was taken as a thin section, stained with lead citrate and uranyl acetate, and examined ultrastructurally (Hafer-Macko et al., 1996) . 
Results
Of the 32 patients in the phase I Cancer Center study, 22 had a baseline neurological evaluation and at least one followup. The patient characteristics are shown in Table 3 . Thirteen of 22 patients had a baseline peripheral neuropathy with a TNS of 2*5. In five of these 13, an aetiology was identified: two had prior chemotherapy, one familial neuropathy, one lymphoedema, and one foot injuries and a history of alcohol use. No patient in cohort I developed new symptoms or signs of neuropathy while receiving suramin. All five patients in cohort II, and 10 of 12 patients in cohort III developed a neuropathy or had worsening of pre-existing neuropathy (Fig. I) . Two patients (both in cohort III) required discontinuation of suramin because of neurological toxicity. Severe neurotoxicity was seen in cohorts II and III only (peak plasma suramin concentrations 3=350 (lg ml" 1 ) and after three or more cycles of treatment. Although no apparent correlation was found between the severity of neuropathy and the cumulative dose ( Fig. 2) , no more precise pharmacodynamic studies to evaluate the relationship between neurotoxicity and suramin pharmacokinetics were undertaken.
Based on the combined clinical, electrodiagnostic, QST and pathological observations, all patients receiving suramin were divided into three groups: (i) asymptomatic patients with minimal or no changes in nerve conduction studies, QST or TNS; (ii) patients with distal symmetrical axonal neuropathy; (iii) patients developing severe, subacutely evolving, demyelinating and inflammatory polyradiculoneuropathy (Figs 3 and 4) . 
Asymptomatic with minimal or no changes in nerve conduction studies, QSTs and TNS
All five patients in cohort I, and two of 12 patients from cohort III, were in this group. One patient complained of decreased dexterity, which was shown to be secondary to development of carpal tunnel syndrome. Three patients showed mild elevation in vibratory threshold, and two had decreased pin sensibility. Strength was normal except in one patient who showed mild weakness of toe extensors. The tendon reflex at the ankle was reduced in two. No significant changes were detected in any of the 12 parameters of the QST and nerve conduction studies except in the median motor conduction velocity (Figs 3 and 4). The average TNS in this group changed from a baseline of 9.3 to 10.7 (Fig. 5) .
Distal axonopathy
Twelve patients (four in cohort II and eight in cohort III) developed signs of distal axonopathy that presented as distal paresthesias (eight patients), weakness (eight patients), or both (four patients). Examination showed reduction of pin sensibility in the feet of 10 patients and elevation of vibratory threshold at the great toe in nine. Eight patients had mild reduction in distal strength of the toe extensors. Deep tendon reflexes were reduced or absent at the ankle in eight patients. Most patients showed a pattern of length-dependent reductions in sensory and motor amplitudes with relative preservation of latencies and conduction velocities, consistent with an axonal polyneuropathy (Figs 3 and 4). Sural and peroneal nerves usually had reduced amplitudes (10 patients). Conduction velocities were relatively preserved, except in two patients in whom median sensory conduction velocities were reduced across the carpal tunnel segment, and were thought to be attributable to development of entrapment neuropathy. Quantitative sensory testing with CASE IV showed worsening of abnormalities to >95th percentile (reference values from Dr P. J. Dyck. Rochester, Minn., USA) of vibratory thresholds in seven patients and of cooling thresholds in six. The average TNS in this group changed from 4.7 to 13.7 (Fig. 5) . Amplitudes (sural and peroneal) were significantly reduced and F-wave latencies (median and peroneal) were significantly increased in the axonal and the demyelinating groups, but not in the normal group. 
Sural Amplitude
Subacute demyelinating and inflammatory polyneuropathy
Three patients (two from cohort III and one from cohort II; Patient 4, Patient 11 and Patient 12 in Fig. 1 ) developed distal paraesthesias followed by subacutely progressive (over 6-8 weeks) proximal weakness (Table 4 and Fig. 6 ). Even after stopping suramin, these patients continued to deteriorate for up to 1 month. One patient became wheelchair-bound, one bed-bound and the third required assistance to walk. All became areflexic, and spinal fluid examination showed albuminocytological dissociation (mean CSF protein = 254 mg dl" 1 ). Nerve conduction studies in these three patients indicated an acquired demyelinating polyneuropathy, showing progressive prolongation of F-wave latencies, reduction in sensory nerve action potential and compound muscle action potential amplitudes and conduction velocities, and abnormal temporal dispersion of evoked responses (Fig. 7) . Average TNS in these patients increased from 3.6 to 26.3 (Fig. 5 ). All were treated with discontinuation of the drug and with plasma exchange and subsequently improved; after 1-2 months, all could walk independently and had minimal symptoms (Fig. 6) .
Case history 1 (Patient 4)
Twelve years prior to evaluation, a 72-year-old man developed adenocarcinoma of the prostate with extra-prostate, pre-rectal extension. Two years after radical prostatectomy and 7000 rads of postoperative radiation therapy, he developed multiple bone lesions and underwent bilateral orchiectomy. After a prolonged response (9 years), his serum prostate specific antigen (PSA) levels increased to 48 ng ml" 1 , rib fractures occurred, and a bone scan showed disease progression despite treatment with flutamide.
He was started on suramin treatment in cohort III. Baseline neurological evaluation revealed no sensory or motor symptoms; normal sensation, strength, and deep-tendon reflexes; and normal nerve conduction and QST measures (TNS = 0). After completing three courses of monthly suramin treatment, he developed numbness and sensory loss limited to the feet. Although suramin was discontinued, these symptoms progressed over the next month to severe disabling numbness, paraesthesias, and pain ascending to the level of the knees. He also developed proximal weakness that initially manifested itself as trouble going up steps but progressed to his becoming wheelchair-bound. Examination showed severe weakness (MRC grade 2) in shoulder abduction and hip flexion, absent deep tendon reflexes, and distal-to-proximal gradient of sensory loss to pin-prick, temperature and vibration to the knees and mid-forearms. Nerve conduction studies showed reductions in sural sensory amplitude, marked prolongations of F-wave latency in median and peroneal nerves, and reductions in conduction velocity in the peroneal, median, and ulnar nerves (Fig. 7) . Needle EMG showed minimal evidence of acute denervation but evidence of reduced recruitment in tested muscles. Quantitative sensory testing showed increased vibratory and thermal thresholds in the feet and hands (TNS had increased to 31). Spinal fluid evaluation showed an elevated protein content (225 mg dl~') with two white cells per millilitre. CSF cytology was negative on three separate occasions. MRI of the C-spine showed no evidence of spinal cord compression. He underwent biopsies of the sural nerve and the vastus lateralis muscle, a weak muscle. Findings for the nerve section are detailed below. The muscle specimen was unremarkable except for mild type II atrophy. In particular, there were no changes of denervation.
He received five plasma exchange treatments (total 250 ml kg" 1 ) over 10 days. After initial worsening, strength began to improve and over the next 2 months he went from using a walker, to a cane, to walking independently, to playing golf (Fig. 6, Patient 4) . A recent examination (1 year after plasma exchange) showed only mild weakness (MRC grade 4 + ) in hip flexion, mild distal sensory loss to the ankles and absent reflexes at the knees and ankles.
Case history 2 (Patient 11)
A 54-year-old man was diagnosed as having prostate cancer and underwent radical prostatectomy 2 years ago. One year later, he was found to have perirectal metastases, was started on monthly injections of leuprolide acetate depo, and received radiation therapy. Later that year, metastatic disease was detected in the liver and bone. Because of progressive disease and rising serum PSA levels, he was enrolled in the suramin treatment phase I study.
Baseline neurological evaluation was normal except for elevated thermal thresholds in the feet on QST (TNS = 2). After three courses of suramin, he felt tired but denied specific sensory or motor symptoms. Examination showed elevated vibratory thresholds at the toes (confirmed by QST) and mild prolongation of median and peroneal F-wave latencies. Following his sixth cycle of treatment, he developed tingling and numbness in his feet, and proximal weakness in the limbs requiring assistance in walking. At its nadir (6 weeks after onset of symptoms), his neuropathy was characterized by moderately severe weakness (MRC grade 3 in shoulder abduction and MRC grade 4 in hip flexion), absent deep-tendon reflexes, and loss of pin-prick and vibration sensibility in a stocking (to ankle)-and-glove (to metacarpophalangeal joint joints) pattern (TNS = 18). Spinal fluid showed 1 white blood cell per millilitre and a protein content of 137 mg dl~'. Nerve conduction studies showed marked prolongation of F-wave latencies and absent H-reflexes (Fig. 7) . He received five courses of plasma exchange treatment (total = 250 ml kg" 1 ) and began to improve 1 month after completing plasma exchange. Over the next 2 months, he improved to near normal functioning (Fig. 6, Patient 11 ).
Case history 3 (Patient 12)
Two and a half years ago a 72-year-old man was diagnosed with metastatic adenocarcinoma of the prostate to lumbosacral spine and pelvis and underwent bilateral orchiectomy. After a 6-month-long response, his bony metastatic disease progressed over the next 2 years, and the serum PSA levels rose progressively.
Baseline neurological evaluation identified no symptoms but disclosed an elevated vibratory threshold on examination and on QST (TNS = 9). After finishing the second course of treatment, he noticed fatigue; after the third course he developed profound weakness in the legs and distally in the hands, accompanied by tingling and numbness in the feet and hands. Examination at the nadir of illness (4 weeks after onset of symptoms) showed marked loss of vibratory sensation up to the knees; absent proprioception at the toes; marked, slightly asymmetric weakness (hip flexion, MRC grade 2/5-he was wheelchair-bound; shoulder abduction, MRC grade 4-5); and areflexia. Nerve conduction studies showed progressive reductions in sural and peroneal amplitude, and prolongation of F-wave and distal motor latencies (Fig. 7) . Abnormal temporal dispersion was noted (TNS = 30). Spinal fluid protein content was elevated to 400 mg dl" 1 without an elevation in white cell count. Cytology from two spinal taps was negative. A sural nerve biopsy was performed (see below).
He received five courses of plasma exchange (total = 250 ml kg" 1 ) and in the next 2 months he gradually improved (Fig. 6) , with all muscles within a range of MRC grade 4 + , distal sensory loss up to the ankles, and normal deeptendon reflexes.
Nerve pathology
The sural nerve biopsy in two patients (Patients 4 and 12) were similar. There was reduction in density of myelinated fibres, and moderate numbers of fibres undergoing Wallerianlike degeneration (Fig. 8A and B) . In addition, there were thinly myelinated fibres and fibres surrounded by minor onion bulbs composed of supernumerary Schwann cell processes ( Fig. 10A) . These latter two features suggested remyelination after previous demyelination.
By immunostaining, there were perivascular lymphocytic cuffs around epineurial vessels and scattered lymphocytes in the endoneurial space (Fig. 8C-G) . Macrophage numbers were increased, and many were enlarged and foamy (Fig. 9 ). At the electron microscopic level, most of the macrophages contained membrane-bound inclusions filled with electron-lucent, amorphous material in a finely fibular matrix (Fig. 10) . The 'thick-thin' comparisons demonstrated unequivocally that the cells containing inclusions were 
Discussion
This prospective study of neuropathy following suramin administration in patients with prostatic cancer identified two distinct patterns, one a distal axonopathy occurring in 55% of the patients in our study and probably a result of direct toxic effect of suramin, and the second a demyelinating neuropathy seen in three patients (18T) secondary to suramininduced immunopathogenic inflammation. Of the 22 prospectively followed patients, neuropathies were found only in those with peak (30-min post-dose) plasma suramin concentrations of 3=350 |ig ml" 1 . Previous reports (La Rocca et a!.. 1990 : Eisenberger et al.. 1995 Kelly et til.. 1995a . b: Kobayashi et al.. 1995 also suggest that se\ere neuropath) occurs predominantly at peak plasma suramin concentrations of 5*350 ug ml 1 and may not be dependent on cumulathe dose. Howe\ er, a recent report by Bitton et al. (1995) suggests that the total cumulative dose in mg kg" 1 , area under the curve above 200 |ig ml" 1 and duration of exposure to plasma suramin concentrations over 200 |ag ml"', are additional predictors of neurotoxicity. However, these conclusions were based on continuous-infusion therapy rather than on the intermittent schedule used by ourselves and most other investigators.
Distal axonopathy
Twelve of 22 patients developed a sensory-motor symmetric polyneuropathy that was length-dependent and axonal by physiological criteria. In previous studies, the lack of a prospective evaluation of neurological function, including nerve conduction testing and QST, prevented determination of the precise incidence of this mild axonal neuropathy. Eisenberger et al. (1993) found axonal neuropathy in up to 40% of patients. In another study (Myers et al., 1992) , up to 79% of patients developed grade 2 sensory neurotoxicity; 16% developed grade 1-2 motor toxicity. The incidence of toxic neuropathy in our study was 55%. We found that the neuropathy affected small and large sensory fibres and motor axons, and the earliest changes occurred distally in sural and peroneal amplitudes, all typical of a 'dying-back' neuropathy (Spencer and Schaumburg, 1978; Schaumburg and Spencer, 1979) . The pathogenetic mechanisms of this suramin-induced distal axonopathy are unclear. In vitro studies have shown that suramin antagonizes the binding of a number of polypeptide growth factor ligands (platelet-derived growth factor, basic fibroblast growth factor, transforming growth factor-fj, and epidermal growth factor) with their receptors (Myers et al., 1991) . In a recent study (Russell et al., 1994) , in vitro suramin-induced damage to dorsal root ganglia was shown to be ameliorated by highdose nerve growth factor, suggesting that nerve growth factor inhibition may be an important component of suramin's neurotoxicity. With the availability of human recombinant nerve growth factor, the dose-limiting toxicity of suramin may indeed be preventable, thus allowing higher dosages of suramin to be used.
Demyelinating neuropathy
Our prospective monitoring also identified three patients who developed a severe, subacutely evolving, demyelinating polyneuropathy that was associated with lymphocytic inflammation in nerve biopsies (Hughes et al., 1992) . The relatively long half-life of suramin (44-54 days) and the 'coasting phenomenon' noted in other toxic neuropathies (Berger et al., 1992) explain the continued worsening after suramin was discontinued. An earlier study (La Rocca et al., 1990) reported a similar neuropathy in four patients who received suramin as a continuous infusion for metastatic adrenal cancer (three) or lymphoma (one). In that study, too, patients were most likely to develop this severe demyelinating neuropathy if they had achieved peak suramin concentrations 3=350 fig ml '. However, unlike the patients in the earlier study, all our patients improved after drug discontinuation and plasma exchange therapy. Although this improvement may have been secondary to our intermittent schedule of suramin therapy, we believe that our prospective monitoring scheme and anticipation of neurological toxicity allowed timely diagnosis and intervention before more severe paralysis or respiratory compromise could take place. Other studies have also reported severe weakness in patients on suramin therapy (Bitton et al., 1995; Eisenberger et al., 1995; Kelly et al., 1995a, b; Kobayashi et al., 1995) but detailed descriptions are lacking to assume that those are similar acquired demyelinating polyneuropathies. In any case, in all these studies the incidence of severe functionally disabling neuropathy is strikingly similar at 10%.
The pathogenetic mechanisms of suramin-induced demyelinating neuropathy, like those of the suramin-induced axonopathy, are unclear. In our three patients, the subacute presentation, the electrodiagnostic studies, the albuminocytologic dissociation, the findings on nerve biopsy (including the lymphocytic inflammation), and the response to plasmapheresis all suggest that suramin may induce an immune-mediated polyneuropathy resembling Guillain-Barre syndrome. Suramin has been shown to alter immunological status of patients by modulating CD4 expression on human peripheral blood lymphocytes (Allen et al., 1993) , and this could potentially lead to altered immune regulation with an autoimmune attack on myelin or one of its components.
We also found Mysosomal inclusions' in the macrophages of the suramin-induced peripheral neuropathy. We did not have biopsy information about any patient with distal axonopathy; thus, we cannot comment on the specificity of this observation to demyelinating neuropathy. However, in humans, suramin is known to cause lysosomal deposits throughout the body, which in turn cause anticoagulation, vortex keratopathy, and probably adrenal gland damage (Myers et al., 1991) . Therefore, these inclusions may not necessarily be specific for a particular pattern of neuropathy. Furthermore, lysosomal inclusions in neuropathies of peripheral nerve seen on electron microscopy have been described in experimental animal models of suramin toxicity (Rees, 1978; Rees et al., 1982) . Suramin inhibits several lysosomal enzymes, including iduronate sulphatase and the acid hydrolase p-hexosaminidase, and this leads to the accumulation of glycosaminoglycans and gangliosides intraand extracellularly. Indeed, suramin can cause a phenocopy of Hunter's syndrome, a form of mucopolysaccharidosis, in rats (Constantopoulos et al., 1980) . Our electrophysiological observation of a few patients showing progressive reduction in conduction velocity across the wrist segment of median nerve (carpal tunnel syndrome) can also be explained by this model of suramin-induced 'mucopolysaccharidosis' (Karpati et al., 1974; Swift and McDonald, 1976) .
In both this and a previous study (Chaudhry et al., 1994) , the TNS was an effective way to monitor patients for development of toxic neuropathy. Total neuropathy score offers several advantages over currently available measures of peripheral nerve function, (i) The battery of studies is simple, direct and short. In our study, TNS was well tolerated and completion of its components took <1 h. (ii) These studies are relatively inexpensive and use tools that are readily available in most university hospital settings, (iii) The test collects information that concentrates on the presence and development of distal neuropathy, the most common in toxic neuropathies, (iv) The data collected can be readily analysed by the physician who collects it, and the TNS can be conveyed to the patient and investigators, (v) An overall picture of neuropathy is obtained, (vi) Correlation to indiviudal measures may help establish which measures are best for following specific toxic neuropathies. For example, in this study the directed neurological examination and the sural and peroneal amplitudes were the most sensitive indicators for the prediction of development of a neuropathy. Studies are underway to confirm the reliability and validity of TNS as an effective tool for monitoring neuropathies.
In conclusion, although suramin may prove to be an effective agent for prostate cancer refractory to hormonal therapy, polyneuropathy is a potentially serious drug-related toxicity that requires careful monitoring, especially if plasma suramin concentrations of >300 \ig ml" 1 are used.
